Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha
- 28 February 1995
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 22 (2), 135-142
- https://doi.org/10.1016/0168-8278(95)80420-x
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitisLiver International, 2008
- Hepatitis B virus markers and antibodies to hepatitis C virus in Japanese patients with hepatocellular carcinomaDigestive Diseases and Sciences, 1992
- Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: Relationship to liver histology and conventional liver testsJournal of Hepatology, 1991
- Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trialJournal of Hepatology, 1990
- Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control groupJournal of Hepatology, 1990
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Is determination of serum N-terminal procollagen type III peptide (sPIIIP) a marker of hepatic fibrosis?Digestive Diseases and Sciences, 1987
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986
- The Blue Glass and the Predictive Value of Serum Amino-Terminal Propeptide of Type III Procollagen as a Marker of Liver FibrosisHepatology, 1984